EpiCept to Present Pre-clinical Advances of Myc Oncogene Directed Drug Discovery
at Assays and Cellular Targets Conference
TARRYTOWN, N.Y., Oct. 15 -- EpiCept Corporation (Nasdaq and OMX Nordic Exchange:
EPCT) today announced that Dr. John Drewe, Senior Director of Lead Discovery,
will be presenting at the IBC conference on Assays and Cellular Targets at the
Hotel Del Coronado in San Diego, CA on October 17, 2007. Dr. Drewe will
describe the advances into pre-clinical testing of drug discovery efforts
targeting the Myc oncogene pathway utilizing EpiCept's Anti-cancer Screening
Apoptosis Platform (ASAP).
(Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO )
The presentation will focus on the rapid identification and optimization of lead
product candidates related to the Myc oncogene pathway which utilized the cell-
and caspase-based apoptosis induction assay for both discovery and successive
structure-activity relationship studies. Oncogenes such as Myc play a key role
in the regulation of processes in both normal and cancer cells. Deregulation of
Myc expression is intimately linked to development of several cancers and has
been a difficult target for drug discovery. EpiCept's ASAP technology provides
a means for identification of compounds targeting the Myc pathway that lead to
apoptosis, or programmed cell death. Optimization by medicinal chemistry has
led to the identification of a compound that is highly efficacious in vivo in
Myc deregulated tumor models. The ASAP technology has also identified two
anticancer drug candidates currently in clinical development, EPC2407 in Phase I
and Azixa(TM)* in Phase II trials.
About EpiCept's ASAP Technology
Cancerous cells often exhibit unchecked growth caused by the disabling or
absence of the natural process of programmed cell death, which is called
apoptosis. Apoptosis is normally triggered to destroy a cell from within when
it outlives its purpose or it is seriously damaged. One of the most promising
approaches in the fight against cancer is to selectively induce apoptosis in
cancer cells, thereby checking, and perhaps reversing, the improper cell growth.
EpiCept's proprietary apoptosis screening technology can efficiently identify
new cancer drug candidates and molecular targets that selectively induce
apoptosis in cancer cells through the use of chemical genetics and its
proprietary live cell high-throughput caspase-3 screening technology.
Chemical genetics is a research approach investigating the effect of small
molecule drug candidates on the cellular activity of a protein, enabling
researchers to determine the protein's function. Using this approach with its
proprietary caspase-3 screening technology, EpiCept researchers can focus their
investigation on the cellular activity of small molecule drug candidates and
their relationship to apoptosis.
This combination of chemical genetics and caspase-3 screening technology allows
EpiCept's researchers to discover and rapidly test the effect of small molecules
on pathways and molecular targets crucial to apoptosis, and gain insights into
their potential as new anticancer agents. This screening technology is
particularly versatile and can be adapted for almost any cell type that can be
cultured, and it can measure caspase activation inside multiple cell types
(e.g., cancer cells, immune cells, or cell lines from different organ systems or
genetically engineered cells). This allows researchers to find potential drug
candidates that are selective for specific cancer types, which may help identify
candidates that provide increased therapeutic benefit and reduced toxicity.
EpiCept has identified several families of compounds with potentially novel
mechanisms that induce apoptosis in cancer cells. Several compounds from within
these families have progressed to lead drug candidate status with proven
pre-clinical efficacies in tumor models and identified molecular targets.
About EpiCept Corporation
EpiCept is focused on unmet needs in the treatment of pain and cancer. EpiCept
has a staged portfolio of pharmaceutical product candidates with several pain
therapies in late-stage clinical trials, and a lead oncology compound (for acute
myeloid leukemia, or AML) with demonstrated efficacy in a Phase III trial; a
marketing authorization application for this compound has been submitted in
Europe. EpiCept is based in Tarrytown, N.Y., and its research and development
team in San Diego is pursuing a drug discovery program focused on novel
approaches to apoptosis.
Forward-Looking Statements
This news release and any oral statements made with respect to the information
contained in this news release, contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements include statements which express plans, anticipation,
intent, contingency, goals, targets, future development and are otherwise not
statements of historical fact. These statements are based on EpiCept's current
expectations and are subject to risks and uncertainties that could cause actual
results or developments to be materially different from historical results or
from any future results expressed or implied by such forward-looking statements.
Factors that may cause actual results or developments to differ materially
include: the risk that the proposed public offering will not be consummated,
the risks associated with our need to raise additional financing to continue to
meet our capital needs and our ability to continue as a going concern, the risk
that Ceplene will not receive regulatory approval or marketing authorization in
the EU or that Ceplene, if approved, will not achieve significant commercial
success, the risk that Myriad's development of Azixa will not be successful, the
risk that Azixa will not receive regulatory approval or achieve significant
commercial success, the risk that we will not receive any significant payments
under our agreement with Myriad, the risk that the development of our other
apoptosis product candidates will not be successful, the risk that our ASAP
technology will not yield any successful product candidates, the risk that
clinical trials for NP-1 or EPC 2407 will not be successful, that NP-1 or EPC
2407 will not receive regulatory approval or achieve significant commercial
success, the risk that our other product candidates that appeared promising in
early research and clinical trials do not demonstrate safety and/or efficacy in
larger-scale or later stage clinical trials, the risk that EpiCept will not
obtain approval to market any of its product candidates, the risks associated
with dependence upon key personnel, the risks associated with reliance on
collaborative partners and others for further clinical trials, development,
manufacturing and commercialization of our product candidates; the cost, delays
and uncertainties associated with our scientific research, product development,
clinical trials and regulatory approval process; our history of operating losses
since our inception; competition; litigation; risks associated with prior
material weaknesses in our internal controls; and risks associated with our
ability to protect our intellectual property. These factors and other material
risks are more fully discussed in EpiCept's periodic reports, including its
reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities
and Exchange Commission. You are urged to carefully review and consider the
disclosures found in EpiCept's filings which are available at www.sec.gov or at
www.epicept.com. You are cautioned not to place undue reliance on any
forward-looking statements, any of which could turn out to be wrong due to
inaccurate assumptions, unknown risks or uncertainties or other risk factors.
EPCT-GEN
*Azixa is a registered trademark of Myriad Genetics, Inc.
SOURCE EpiCept Corporation
-0- 10/15/2007
/CONTACT: Robert W. Cook of EpiCept Corporation, +1-914-606-3500,
rcook@epicept.com; Media, Greg Kelley of Feinstein Kean Healthcare,
+1-617-577-8110, gregory.kelley@fkhealth.com; Investors, Kim Sutton Golodetz,
+1-212- 838-3777, kgolodetz@lhai.com or Bruce Voss, +1-310-691-7100,
bvoss@lhai.com, both of Lippert Heilshorn & Associates/
/Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com/
/Web site: http://www.epicept.com /
(EPCT)
EpiCept to Present Pre-clinical Advances of Myc Oncogene Directed Drug Discovery at Assays and Cellular Targets Conference
| Source: Immune Pharmaceuticals Inc